DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

HIV prevention with your patients' tomorrow in mind

HIV risk does not discriminate—it affects sexually active individuals of all ages and can last throughout their lives1

Renal exposure may matter more over time2,3

Markers of renal function that can be affected by exposure to certain drugs include:

• eGFR

• Serum creatinine

Graph Showing Mean GFR Values in Normal Males

Reprinted with permission from Elsevier.3

Bone density is crucial for your patients of any age4-6

• Under 30: They are often still building bone

• Over 40: They may already be experiencing bone mineral density declines

Graph Showing Bone Mass Across Life Span in Males

Adapted by permission from Springer Nature: Osteoporosis International. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations, Weaver CM, Gordon CM, Janz KF, et al, 2016.5

Considering your patients' overall health is a key factor when prescribing any drug—including PrEP medications.

eGFR=estimated glomerular filtration rate; NSAIDs=nonsteroidal anti-inflammatory drugs.